Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335 that is in Phase IIb clinical trial for the treatment of pet dogs with cancer, as well as Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-658-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.34 million
Profitability
Miscellaneous
Employees332
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
How were Karyopharm Therapeutics' earnings last quarter?
Karyopharm Therapeutics Inc (NASDAQ:KPTI) released its quarterly earnings results on Thursday, February, 28th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.09. Karyopharm Therapeutics had a negative return on equity of 107.60% and a negative net margin of 588.10%. View Karyopharm Therapeutics' Earnings History.
When is Karyopharm Therapeutics' next earnings date?
What price target have analysts set for KPTI?
10 Wall Street analysts have issued twelve-month price objectives for Karyopharm Therapeutics' shares. Their forecasts range from $5.00 to $30.00. On average, they expect Karyopharm Therapeutics' stock price to reach $19.2222 in the next year. This suggests a possible upside of 249.5% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.
What is the consensus analysts' recommendation for Karyopharm Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.
What are Wall Street analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
- 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (3/2/2019)
- 2. HC Wainwright analysts commented, "We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and an estimated early stage pipeline value of $0.86/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x." (2/27/2019)
Has Karyopharm Therapeutics been receiving favorable news coverage?
Press coverage about KPTI stock has been trending somewhat positive on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Are investors shorting Karyopharm Therapeutics?
Karyopharm Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totalling 7,620,678 shares, an increase of 27.7% from the January 31st total of 5,966,053 shares. Based on an average daily trading volume, of 1,310,018 shares, the short-interest ratio is currently 5.8 days. Currently, 14.7% of the company's shares are sold short. View Karyopharm Therapeutics' Current Options Chain.
Who are some of Karyopharm Therapeutics' key competitors?
Some companies that are related to Karyopharm Therapeutics include Clovis Oncology (CLVS), Theravance Biopharma (TBPH), Cambrex (CBM), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Epizyme (EPZM), Rhythm Pharmaceuticals (RYTM), Inflarx (IFRX), Ra Pharmaceuticals (RARX), Clementia Pharmaceuticals (CMTA) and Tricida (TCDA).
What other stocks do shareholders of Karyopharm Therapeutics own?
Who are Karyopharm Therapeutics' key executives?
Karyopharm Therapeutics' management team includes the folowing people:
- Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
- Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
- Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
- Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
- Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)
Who are Karyopharm Therapeutics' major shareholders?
Karyopharm Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.01%), Ridgeback Capital Investments L.P. (6.50%), FMR LLC (3.09%), Candriam Luxembourg S.C.A. (2.95%), Emerald Advisers LLC (2.40%) and Emerald Mutual Fund Advisers Trust (2.26%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.
Which institutional investors are selling Karyopharm Therapeutics stock?
KPTI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Barclays PLC, D. E. Shaw & Co. Inc., Frontier Capital Management Co. LLC, Private Capital Advisors Inc., Northern Trust Corp, MetLife Investment Advisors LLC and Bank of America Corp DE. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.
Which institutional investors are buying Karyopharm Therapeutics stock?
KPTI stock was acquired by a variety of institutional investors in the last quarter, including Ridgeback Capital Investments L.P., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Candriam Luxembourg S.C.A., FMR LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP and Two Sigma Investments LP. View Insider Buying and Selling for Karyopharm Therapeutics.
How do I buy shares of Karyopharm Therapeutics?
Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Karyopharm Therapeutics' stock price today?
One share of KPTI stock can currently be purchased for approximately $5.50.
How big of a company is Karyopharm Therapeutics?
Karyopharm Therapeutics has a market capitalization of $334.73 million and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.
What is Karyopharm Therapeutics' official website?
How can I contact Karyopharm Therapeutics?
Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]
MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
